An Open Label Phase 1, First-In-Human Study of TRAIL Receptor Agonist ABBV-621 in Subjects with Previously-Treated Solid Tumors and Hematologic Malignancies

Protocol No
ABBVIE-M15-913
Principal Investigator
Aditya Shreenivas
Phase
I
Summary
ABBV-621 is a tumor necrosis factor (TNF)- related apoptosis-inducing ligand (TRAIL) receptor agonist. ABBV-621 promotes apoptosis (a common way that cells die) by binding to death receptors on the outside of cells, which starts the cell death process. In this study the ABBV-621 will be tested as a single agent and in combination with ventetoclax in various hematologic malignancies.
Description
A Study of the Safety and Tolerability of ABBV-621 in Participants With Previously Treated Solid Tumors and Hematologic Malignancies
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Share This: